NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, today announced the appointment of
Michael Rabinowitz to the newly
created position of Chief Commercial Officer effective August 1, 2021. Mr. Rabinowitz will be
responsible for Oramed's overall commercial strategy and
execution.
"As we move through the Phase III trials of our oral insulin,
ORMD-0801, we are looking ahead towards the next step:
commercialization. We're very pleased to welcome Michael
Rabinowitz as Oramed's first Chief Commercial
Officer. Michael's years of global commercial experience make
him the ideal leader for Oramed's next phase of growth and
development. Throughout his career, he has built a strong
track record in successfully launching new products and
will certainly play a vital role in commercializing Oramed's
pipeline," stated Oramed Chief Executive Officer, Nadav Kidron.
Mr. Rabinowitz is a highly accomplished commercial leader
having spent over 20 years at the global biopharmaceutical company
Merck & Co. serving in marketing, sales, business development,
and financial leadership roles in the U.S. and globally. At Merck,
he launched and marketed products in over 30 countries across
several disease areas, including launching billion-dollar oral
agents in diabetes and managing a global business. Mr. Rabinowitz
holds a Masters' Degree from The Carlson School of Management,
University of Minnesota. He has also participated in
executive health care programs at the Harvard
Business School.
"I am very excited to join Oramed and work with the team to
advance healthcare through Oramed's innovative technology," said
Mr. Rabinowitz.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals
(Nasdaq/TASE: ORMP) is a platform technology pioneer in the
field of oral delivery solutions for drugs currently delivered via
injection. Established in 2006, with offices in the United
States and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology. Oramed is seeking to transform the
treatment of diabetes through its proprietary lead
candidate, ORMD-0801, which is being evaluated in two pivotal
Phase III studies and has the potential to be the first commercial
oral insulin capsule for the treatment of diabetes. In
addition, Oramed is developing an oral GLP-1 (Glucagon-like
peptide-1) analog capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential
commercialization of ORMD-0801 and pipeline, the
potential benefits of ORMD-0801 or revolutionizing the
treatment of diabetes with our products. In addition, historic
results of scientific research and clinical trials do not guarantee
that the conclusions of future research or trials will suggest
identical or even similar conclusions. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Josh
Hexter
+1-844-9-ORAMED
josh@oramed.com
Logo -
https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oramed-pharmaceuticals-appoints-chief-commercial-officer-301344191.html
SOURCE Oramed Pharmaceuticals Inc.